Skip to main content

Advertisement

SpringerLink
Log in

Lactoferrin-Decorated Cerium Oxide Nanoparticles Prevent Renal Injury and Fibrosis

  • Published:
Biological Trace Element Research Aims and scope Submit manuscript

Abstract

Renal fibrosis is a hallmark feature of chronic kidney diseases (CKDs). However, despite the increased prevalence of renal fibrosis, there is no approved antifibrotic drug for the management of renal fibrosis. Cerium oxide nanoparticles (CONPs) have been demonstrated to possess a number of properties including antioxidant, anti-inflammatory and nephroprotective activity. As the kidneys are rich in lactoferrin (Lf) receptors, we synthesised the lactoferrin-CONP (Lf-CONP) system to be used for active targeting of the kidneys and provide antifibrotic effects of CONPs to the kidneys. We used the unilateral ureteral obstruction (UUO)–induced renal fibrosis model and treated the animals with Lf-CONP to observe the antifibrotic effects of Lf-CONP. Lf-CONP was found to inhibit the progression of renal fibrosis in a superior manner when compared to CONPs alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

Available on request

References

  1. Lv W, Booz GW, Fan F et al (2018) Oxidative stress and renal fibrosis: recent insights for the development of novel therapeutic strategies. Front Physiol 9:105

    Article  PubMed  PubMed Central  Google Scholar 

  2. Su H, Wan C, Song A et al (2019) Oxidative stress and renal fibrosis: mechanisms and therapies. Ren Fibros Mech Ther 1165:585–604

  3. Honda T, Hirakawa Y, Nangaku M (2019) The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract 38:414–426

    Article  PubMed  PubMed Central  Google Scholar 

  4. François H, Chatziantoniou C (2018) Renal fibrosis: recent translational aspects. Matrix Biol 68:318–332

    Article  PubMed  Google Scholar 

  5. Meng X, Nikolic-Paterson DJ, Lan HY (2016) TGF-β: the master regulator of fibrosis. Nat Rev Nephrol 12:325–338

    Article  CAS  PubMed  Google Scholar 

  6. Najafi R, Hosseini A, Ghaznavi H et al (2017) Neuroprotective effect of cerium oxide nanoparticles in a rat model of experimental diabetic neuropathy. Brain Res Bull 131:117–122

    Article  CAS  PubMed  Google Scholar 

  7. Pourkhalili N, Hosseini A, Nili-Ahmadabadi A et al (2011) Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats. World J Diabetes 2:204–210

    Article  PubMed  PubMed Central  Google Scholar 

  8. Oró D, Yudina T, Fernández-Varo G et al (2016) Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J Hepatol 64:691–698

    Article  PubMed  Google Scholar 

  9. Chen J, Patil S, Seal S, McGinnis JF (2006) Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 1:142–150

    Article  CAS  PubMed  Google Scholar 

  10. Nelson BC, Johnson ME, Walker ML et al (2016) Antioxidant cerium oxide nanoparticles in biology and medicine. Antioxidants 5:15

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nourmohammadi E, Khoshdel-Sarkarizi H, Nedaeinia R et al (2019) Evaluation of anticancer effects of cerium oxide nanoparticles on mouse fibrosarcoma cell line. J Cell Physiol 234:4987–4996

    Article  CAS  PubMed  Google Scholar 

  12. Hirst SM, Karakoti AS, Tyler RD et al (2009) Anti-inflammatory properties of cerium oxide nanoparticles. Small 5:2848–2856

    Article  CAS  PubMed  Google Scholar 

  13. Popov AL, Zaichkina SI, Popova NR et al (2016) Radioprotective effects of ultra-small citrate-stabilized cerium oxide nanoparticles in vitro and in vivo. RSC Adv 6:106141–106149

    Article  CAS  Google Scholar 

  14. Saifi MA, Peddakkulappagari CS, Ahmad A, Godugu C (2020) Leveraging the pathophysiological alterations of obstructive nephropathy to treat renal fibrosis by cerium oxide nanoparticles. ACS Biomater Sci Eng 6:3563–3573

    Article  CAS  PubMed  Google Scholar 

  15. Liang X, Wang H, Zhu Y et al (2016) Short-and long-term tracking of anionic ultrasmall nanoparticles in kidney. ACS Nano 10:387–395

    Article  CAS  PubMed  Google Scholar 

  16. Åbrink M, Larsson E, Gobl A, Hellman L (2000) Expression of lactoferrin in the kidney: implications for innate immunity and iron metabolism. Kidney Int 57:2004–2010

    Article  PubMed  Google Scholar 

  17. Hsu Y-H, Chiu I-J, Lin Y-F et al (2020) Lactoferrin contributes a renoprotective effect in acute kidney injury and early renal fibrosis. Pharmaceutics 12:434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Annaldas S, Saifi MA, Khurana A, Godugu C (2019) Nimbolide ameliorates unilateral ureteral obstruction-induced renal fibrosis by inhibition of TGF-β and EMT/Slug signalling. Mol Immunol 112:247–255

    Article  CAS  PubMed  Google Scholar 

  19. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358

    Article  CAS  PubMed  Google Scholar 

  20. Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys acta (BBA)-general Subj 582:67–78

    Article  CAS  Google Scholar 

  21. Bansod S, Godugu C (2021) Nimbolide ameliorates pancreatic inflammation and apoptosis by modulating NF-κB/SIRT1 and apoptosis signaling in acute pancreatitis model. Int Immunopharmacol 90:107246

    Article  CAS  PubMed  Google Scholar 

  22. Neuman RE, Logan MA (1950) The determination of hydroxyproline. J Biol Chem 184:299–306

    Article  CAS  PubMed  Google Scholar 

  23. Sravani S, Saifi MA, Godugu C (2020) Riociguat ameliorates kidney injury and fibrosis in an animal model. Biochem Biophys Res Commun 530:706–712

    Article  CAS  PubMed  Google Scholar 

  24. Jester JV, Barry-Lane PA, Petroll WM et al (1997) Inhibition of corneal fibrosis by topical application of blocking antibodies to TGF beta in the rabbit. Cornea 16:177–187

    Article  CAS  PubMed  Google Scholar 

  25. Yanagita M (2012) Inhibitors/antagonists of TGF-β system in kidney fibrosis. Nephrol Dial Transplant 27:3686–3691

    Article  CAS  PubMed  Google Scholar 

  26. Pat B, Yang T, Kong C et al (2005) Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int 67:931–943

    Article  CAS  PubMed  Google Scholar 

  27. Kawai Y, Satoh T, Hibi D et al (2009) The effect of antioxidant on development of fibrosis by cisplatin in rats. J Pharmacol Sci 111:433–439

    Article  CAS  PubMed  Google Scholar 

  28. Chade AR, Rodriguez-Porcel M, Herrmann J et al (2004) Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 15:958–966

    Article  CAS  PubMed  Google Scholar 

  29. Hirst SM, Karakoti A, Singh S et al (2013) Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol 28:107–118

    Article  CAS  PubMed  Google Scholar 

  30. Lesná J, Tichá A, Hyšpler R et al (2015) Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutr Diabetes 5:e183–e183

    Article  PubMed  PubMed Central  Google Scholar 

  31. Grey A, Banovic T, Zhu Q et al (2004) The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268–2278

    Article  CAS  PubMed  Google Scholar 

  32. Ando K, Hasegawa K, Shindo K et al (2010) Human lactoferrin activates NF-κB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling. FEBS J 277:2051–2066

    Article  CAS  PubMed  Google Scholar 

  33. Takayama Y, Aoki R, Uchida R et al (2017) Role of CXC chemokine receptor type 4 as a lactoferrin receptor. Biochem Cell Biol 95:57–63

    Article  CAS  PubMed  Google Scholar 

  34. Penco S, Caligo MA, Cipollini G et al (1999) Lactoferrin expression in human breast cancer. Cancer Biochem Biophys 17:163–178

    CAS  PubMed  Google Scholar 

  35. Benaïssa M, Peyrat J, Hornez L et al (2005) Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J cancer 114:299–306

    Article  PubMed  Google Scholar 

  36. Abdelmoneem MA, Mahmoud M, Zaky A et al (2018) Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma. Nanomedicine 13:2377–2395

    Article  CAS  PubMed  Google Scholar 

  37. Hakim F, Wang Y, Zhang SXL et al (2014) Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling. Cancer Res 74:1329–1337

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Bezault J, Bhimani R, Wiprovnick J, Furmanski P (1994) Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 54:2310–2312

    CAS  PubMed  Google Scholar 

  39. Lord MS, Farrugia BL, Yan CMY et al (2016) Hyaluronan coated cerium oxide nanoparticles modulate CD44 and reactive oxygen species expression in human fibroblasts. J Biomed Mater Res Part A 104:1736–1746

    Article  CAS  Google Scholar 

  40. Hijaz M, Das S, Mert I et al (2016) Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer. BMC Cancer 16:1–14

    Article  Google Scholar 

  41. Zhao H, Liu Y, Liu Z et al (2017) Role of mitochondrial dysfunction in renal fibrosis promoted by hypochlorite-modified albumin in a remnant kidney model and protective effects of antioxidant peptide SS-31. Eur J Pharmacol 804:57–67

    Article  CAS  PubMed  Google Scholar 

  42. Liu H, Wu H, Zhu N et al (2020) Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced Parkinson’s disease in mice. J Neurochem 152:397–415

    Article  CAS  PubMed  Google Scholar 

  43. Safaeian L, Javanmard SH, Mollanoori Y, Dana N (2015) Cytoprotective and antioxidant effects of human lactoferrin against H2O2-induced oxidative stress in human umbilical vein endothelial cells. Adv Biomed Res 4:188

    PubMed  PubMed Central  Google Scholar 

  44. Han N, Li H, Li G et al (2019) Effect of bovine lactoferrin as a novel therapeutic agent in a rat model of sepsis-induced acute lung injury. AMB Express 9:1–8

    Article  Google Scholar 

  45. Hegazy R, Salama A, Mansour D, Hassan A (2016) Renoprotective effect of lactoferrin against chromium-induced acute kidney injury in rats: involvement of IL-18 and IGF-1 inhibition. PLoS ONE 11:e0151486

    Article  PubMed  PubMed Central  Google Scholar 

  46. Akhtar MJ, Ahamed M, Alhadlaq HA et al (2015) Glutathione replenishing potential of CeO2 nanoparticles in human breast and fibrosarcoma cells. J Colloid Interface Sci 453:21–27

    Article  CAS  PubMed  Google Scholar 

  47. Kumari P, Saifi MA, Khurana A, Godugu C (2018) Cardioprotective effects of nanoceria in a murine model of cardiac remodeling. J Trace Elem Med Biol 50:198–208

    Article  CAS  PubMed  Google Scholar 

  48. Wallach TE, Srivastava V, Reyes E et al (2019) Lactoferrin reverses methotrexate driven epithelial barrier defect by inhibiting TGF-β mediated epithelial to mesenchymal transition. bioRxiv

  49. Guo C, Smith R, Gant TW, Leonard MO (2015) Cerium dioxide nanoparticles protect against oxidative stress induced injury through modulation of TGF-β signalling. Toxicol Res (Camb) 4:464–475

    Article  CAS  Google Scholar 

  50. Domala A, Bale S, Godugu C (2020) Protective effects of nanoceria in imiquimod induced psoriasis by inhibiting the inflammatory responses. Nanomedicine 15:5–22

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would also like to acknowledge Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India and the Director, NIPER-Hyderabad.

Funding

The authors would like to thank the Department of Biotechnology (DBT), Govt. of India, for the financial support via North East-Twinning Grant to Dr. CG (MAP/2015/58), DBT Indo-Brazil Grant DBT/IC-2/Indo-Brazil/2016–19/01, and the Department of Science and Technology-Science and Engineering Board-Early Career Research Award (SERB-ECR) Grant ECR/2016/000007.

Author information

Authors and Affiliations

  1. Department of Biological Sciences (Regulatory Toxicology), National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India

    Mohd Aslam Saifi, Rishabh Hirawat & Chandraiah Godugu

Authors
  1. Mohd Aslam Saifi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rishabh Hirawat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chandraiah Godugu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MAS performed the experiments, collected the data, analysed the results and prepared the draft of the manuscript. RH helped in analysing the results and contributed to the writing of the manuscript. CG designed the experiment, provided the facilities, supervised the work, edited the manuscript draft and approved the publication of the manuscript.

Corresponding author

Correspondence to Chandraiah Godugu.

Ethics declarations

Ethics Approval

The experiments were conducted after obtaining approval from the Institutional Animal Ethics Committee (IAEC, NIP/01/2018/RT/277). All the experiments were performed in accordance with the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aslam Saifi, M., Hirawat, R. & Godugu, C. Lactoferrin-Decorated Cerium Oxide Nanoparticles Prevent Renal Injury and Fibrosis. Biol Trace Elem Res 201, 1837–1845 (2023). https://doi.org/10.1007/s12011-022-03284-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12011-022-03284-6

Keywords

Search

Navigation